Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment, but has not been implicated in cases of clinically apparent acute liver injury.
Pramipexole (pram" i pex' ole) is synthetic, nonergot derivative and dopamine receptor agonist that has selective activity for the D2 class of dopamine receptors and little agonist activity for the D1 class. For this reason, pramipexole may be better tolerated than bromocriptine or pergolide which have activity for both D1 and D2 receptors. Pramipexole was approved for use in the United States in 1997 for the therapy of symptomatic Parkinson disease. Pramipexole is available in tablets of 0.125, 0.25, 0.5, 1 and 1.5 mg generically and under the brand name of Miraplex. It is used often, but not always in combination with levodopa/carbidopa. Pramipexole is typically initiated in low doses (0.375 mg in 3 divided doses daily), with adjustment upwards based upon tolerance and clinical effects. The typical maintenance dose for Parkinson disease is 1.5 to 4.5 mg daily in three divided doses. Pramipexole can be initiated more quickly than bromocriptine or pergolide, and does not cause the profound hypotension and nausea that are typical of the ergot derivatives. Common side effects include somnolence, fatigue, vivid dreams, anxiety, confusion, depression, dizziness, headache and gastrointestinal upset.
Pramipexole has been reported to cause serum aminotransferase elevations in a small proportion of patients, but these abnormalities are usually mild, asymptomatic and self-limiting even without dose adjustment. Pramipexole has not been implicated in cases of clinically apparent acute liver injury which must be rare, if it occurs at all.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
Mechanism of Injury
Pramipexole is minimally metabolized by the liver and is excreted largely unchanged in the urine.
Outcome and Management
Instances of liver injury attributed to pramipexole have been mild, asymptomatic and self-limiting. No instances of acute liver failure or chronic injury have been reported.
REPRESENTATIVE TRADE NAMES
Pramipexole – Generic, Mirapex®
Product labeling at DailyMed, National Library of Medicine, NIH
||CAS REGISTRY NUMBER
Top of page
updated: 20 July 2017
HJ. Antiparkinsonism drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse
effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia:
Lippincott, 1999, pp. 715-7. (Expert
review of hepatotoxicity published in 1999; among anticholinergic agents, "only
trihexyphenidyl has been incriminated in hepatic injury"; other antiparkinsonism
drugs discussed include levodopa, lergotrile [no longer available], pergolide
D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In,
Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam:
Elsevier Inc, 2013, pp. 443-62. (Review
of hepatotoxicity of agents acting on the central nervous system).
DG, Roberson ED. Treatment of central nervous system degenerative disorders. In,
Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the
pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp.
of pharmacology and therapeutics).
F. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological
aspects. Clinical laboratory abnormalities. Clin Pharmacol Ther 1971; 12:
analysis of laboratory abnormalities arising in 974 patients with Parkinson
disease treated with levodopa; AST elevations occurred in 9% of 5427
determinations, but were usually mild and transient returning to normal in 1-2
months without dose adjustment; AST levels rose to 1600 U/L in one patient who
later died of complications of diabetes).
Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-47. PubMed Citation (55 patients with early Parkinson disease where treated with selegiline and either pramipexole or placebo for 9 weeks; one patient in each group had an asymptomatic, isolated elevation in AST).
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-8. PubMed Citation (Among 360 patients with advanced Parkinson disease on levodopa/carbidopa treated with pramipexole or placebo, side effects were similar in the two groups; no mention of ALT abnormalities or hepatotoxicity).
Shannon KM, Bennett JP Jr., Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-8. PubMed Citation (In a controlled trial of pramipexole vs placebo in 335 patients with early Parkinson disease not receiving levodopa, there were no significant changes in serum chemistry test results in either group).
D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian
agents. Drugs Aging 2000; 16: 55-65. PubMed
of mechanism of action, tolerability and safety of selegiline, pramipexole,
ropinirole, tolcapone and entacapone in Parkinson disease).
Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver
failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52:
Citation (Among 1198 patients
with acute liver failure enrolled in a US prospective study between 1998 and
2007, 133 were attributed to drug induced liver injury, but none were attributed
to agents used for Parkinson disease).
ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation,
and outcomes in patients with drug-induced liver injury in the general
population of Iceland. Gastroenterology 2013; 144: 1419-25,1425. PubMed
Citation (In a population
based study of drug induced liver injury from Iceland, 96 cases were identified
over a 2 year period, but none of the 96 were attributed to an agent used to
treat Parkinson disease).
for Parkinson's disease. Treat Guidel Med Lett 2013; 11 (135):
Citation (Concise review of
recommendations for therapy of Parkinson disease with description of mechanisms
of action, efficacy and adverse events).
N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al.
Profile of idiosyncratic drug induced liver injury in Latin America: an analysis
of published reports. Ann Hepatol 2014; 13: 231-9. PubMed Citation (Among 176 reports
of drug induced liver injury from Latin America published between 1996 and 2012,
none were attributed to an agent to treat Parkinson disease).
N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.;
United States Drug Induced Liver Injury Network. Features and outcomes of 899
patients with drug-induced liver injury: The DILIN Prospective Study.
Gastroenterology 2015; 148: 1340-52. PubMed
Citation (Among 899 cases of
drug induced liver injury from the US enrolled in a prospective database between
2004 and 2012, none were attributed to an agent used to treat Parkinson
OTHER REFERENCE LINKS
Top of page